In a former study by Calverley et al., patients with COPD were treated with a human immunoglobulin G2 monoclonal antibody targeting IL1R1 called MEDI8968 (ClinicalTrials.gov identifier: NCT01448850) to prevent acute exacerbations [24]. The gene discussed is IL1R1; the disease is chronic obstructive pulmonary disease.